Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03193229 · ClinicalTrials.gov registry record · NA
MapTrek to Increase Activity Among Patients at Risk for Type 2 Diabetes
A NA study, sponsored by Philip Polgreen.
- Completed
- Registry status
- NA
- Development phase
- 430
- Enrollment target
NCT03193229 is a NA study that has completed, run by Philip Polgreen. The registered enrollment target is 430 participants.
The verdict
NCT03193229, a NA study, has completed, sponsored by Philip Polgreen.
- COMPLETED
- Registry status
- NA
- Development phase
- 430 participants
- Enrollment target
Study Summary
The overarching objective of our work is to provide an inexpensive and scalable m-health tool to increase both volume and intensity of physical activity and reduce sedentary behavior in patients at risk for type 2 diabetes. The objective of this study is to pilot test MapTrek, a text-messaging based intervention.
Interventions
- DEVICE Fitbit
- BEHAVIORAL MapTrek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2018-05-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03193229
The ClinicalTrials.gov registry entry for NCT03193229 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Philip Polgreen, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fitbit is the first listed.
NCT03193229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03193229 about?
NCT03193229 is a clinical study titled "MapTrek to Increase Activity Among Patients at Risk for Type 2 Diabetes". The overarching objective of our work is to provide an inexpensive and scalable m-health tool to increase both volume and intensity of physical activity and reduce sedentary behavior in patients at risk for type 2 diabetes. The objective of this study is to pilot test MapTrek, a text-messaging based...
What is the current status of trial NCT03193229?
This trial is currently completed. It is a NA study. The enrollment target is 430 participants. The study started on 2017-05-15. Estimated completion is 2018-05-04.
What interventions are being tested in trial NCT03193229?
The interventions under investigation include: Fitbit (DEVICE), MapTrek (BEHAVIORAL).
Who is sponsoring clinical trial NCT03193229?
This trial is sponsored by Philip Polgreen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.